Medical Pharmacology Question Bank

Chapter 1: General Pharmacology — Module 5: Drug Development and Regulation
Tier: Tier 4 — Extended Clinical Cases

1. Pharmacogenomic testing returns: CYP2C19 *2/*2 genotype (poor metabolizer). Which of the following best explains why this result is critically important in the context of this patient's post-stent management, and what the PRU value of 248 indicates about his current antiplatelet protection?

A) CYP2C19 *2/*2 genotype indicates the patient is a CYP2C19 ultrarapid metabolizer who is rapidly clearing clopidogrel before it can be converted to its active metabolite — the PRU of 248 confirms adequate platelet inhibition and no change in therapy is required
B) CYP2C19 *2/*2 genotype indicates the patient is a CYP2C19 poor metabolizer carrying two loss-of-function alleles — clopidogrel cannot be adequately bioactivated to its active thiol metabolite; the PRU of 248 confirms inadequate platelet P2Y12 receptor inhibition (therapeutic target <208), meaning this patient has high on-treatment platelet reactivity (HTPR) and is at substantially elevated risk of stent thrombosis, recurrent myocardial infarction, and cardiovascular death despite apparent clopidogrel compliance; this pharmacogenomic result demands immediate antiplatelet therapy reassessment
C) CYP2C19 *2/*2 genotype indicates the patient is a CYP2C19 intermediate metabolizer with partially preserved bioactivation capacity — the PRU of 248 is only slightly above the therapeutic threshold and the patient can continue clopidogrel with dose doubling to 150 mg daily to compensate for reduced bioactivation
D) The PRU value of 248 confirms adequate clopidogrel effect regardless of CYP2C19 genotype — platelet function testing supersedes pharmacogenomic testing in clinical decision-making and the CYP2C19 *2/*2 result can be disregarded if the PRU demonstrates therapeutic platelet inhibition
E) CYP2C19 *2/*2 genotype is pharmacogenomically relevant only for gastrointestinal indications (proton pump inhibitor dosing) and has no established clinical significance for clopidogrel bioactivation or antiplatelet efficacy

ANSWER: B

Rationale:

CYP2C19 *2 is the most common loss-of-function allele in the CYP2C19 gene — a splice-site variant (c.681G>A, rs4244285) that produces aberrant splicing and a truncated, non-functional CYP2C19 protein. Patients homozygous for CYP2C19 *2 (genotype *2/*2) are poor metabolizers with essentially absent CYP2C19 enzymatic activity. Clopidogrel is a thienopyridine prodrug requiring two-step hepatic bioactivation — the first and rate-limiting step is CYP2C19-mediated oxidation to a thiolactone intermediate, which is then further oxidized (also CYP2C19-dependent) to the active thiol metabolite. This active metabolite irreversibly alkylates the cysteine-17 residue of the platelet P2Y12 ADP receptor, blocking ADP-induced platelet aggregation for the platelet's lifespan. In CYP2C19 *2/*2 poor metabolizers, this bioactivation pathway is essentially non-functional — active metabolite generation is dramatically reduced (by 70–90% compared to EM patients), and the resulting platelet P2Y12 inhibition is clinically inadequate. The PRU value of 248 confirms this pharmacogenomic consequence: a PRU >208 indicates high on-treatment platelet reactivity (HTPR), reflecting insufficient P2Y12 receptor blockade. In the context of a recently stented patient (drug-eluting stent placed six weeks ago, during the highest-risk window for stent thrombosis), HTPR from CYP2C19 PM status represents a serious and potentially life-threatening gap in antiplatelet protection. The anemia (Hgb 9.8 from baseline 14.2) in the absence of overt bleeding may reflect occult gastrointestinal bleeding from aspirin — a separate clinical concern requiring evaluation — but the primary pharmacogenomic urgency is the inadequate antiplatelet protection. CYP2C19 *2/*2 prevalence in Chinese populations is approximately 15%, making PM status more common than in European populations (~2–5%). Option A incorrectly identifies *2/*2 as UM — UM phenotype results from *17 gain-of-function alleles; *2 is loss-of-function. Option C incorrectly assigns IM status to *2/*2 — two loss-of-function alleles produce PM, not IM phenotype. Option D is incorrect — while platelet function testing is a valuable phenotypic measure, a PRU of 248 confirms inadequate inhibition (not adequate); the statement is internally contradictory. Option E is incorrect — CYP2C19 pharmacogenomics has its strongest and most extensively validated clinical evidence base for clopidogrel, not PPIs; FDA boxed warning specifically applies to clopidogrel.

2. Based on the CYP2C19 *2/*2 poor metabolizer status and confirmed HTPR (PRU 248), the cardiologist considers switching antiplatelet therapy. Two alternatives to clopidogrel are available: prasugrel and ticagrelor. Which of the following best characterizes the pharmacogenomic and pharmacological basis for preferring one of these agents over clopidogrel in this patient, and identifies any patient-specific contraindication that must be assessed?

A) Prasugrel is preferred over ticagrelor because prasugrel requires CYP2C19 bioactivation and therefore remains active in poor metabolizers; ticagrelor is a CYP2C19 substrate and would be equally ineffective as clopidogrel in this patient
B) Both prasugrel and ticagrelor are appropriate alternatives to clopidogrel in CYP2C19 poor metabolizers because neither requires CYP2C19 for bioactivation — prasugrel is a prodrug activated primarily by CYP3A4 and CYP2B6 (not CYP2C19), producing reliable active metabolite generation regardless of CYP2C19 status; ticagrelor is a direct-acting reversible P2Y12 antagonist that does not require hepatic bioactivation at all; before selecting prasugrel, the patient must be assessed for prior stroke or TIA (absolute contraindication), age ≥75 years, and body weight <60 kg (relative contraindications associated with net clinical harm in prasugrel trials); ticagrelor is generally preferred in East Asian populations where prasugrel's bleeding risk may be amplified
C) Neither prasugrel nor ticagrelor is appropriate for Chinese patients because both drugs are metabolized by CYP2C19 and will be equally ineffective as clopidogrel in CYP2C19 poor metabolizers — genotype-guided dose escalation of clopidogrel to 300 mg daily is the only pharmacogenomically supported strategy
D) Prasugrel requires no pharmacogenomic consideration because it is administered as an active drug requiring no hepatic metabolism — it directly blocks P2Y12 receptors without prodrug activation; ticagrelor requires CYP2C19 bioactivation and is therefore preferred only in CYP2C19 extensive metabolizers
E) Ticagrelor is contraindicated in patients with recent STEMI because its reversible P2Y12 antagonism allows platelet reactivity to recover within 24 hours of each dose, producing a daily window of inadequate platelet inhibition and increased stent thrombosis risk in the perioperative period

ANSWER: B

Rationale:

This question requires precise knowledge of the bioactivation requirements and pharmacogenomic independence of the three P2Y12 inhibitor classes. Clopidogrel's dependence on CYP2C19 bioactivation — and the consequent vulnerability of its efficacy to CYP2C19 PM status — is the pharmacogenomic vulnerability that necessitates considering alternatives. Prasugrel is a third-generation thienopyridine prodrug that undergoes intestinal esterase-mediated hydrolysis followed by CYP3A4 and CYP2B6-mediated oxidation to its active thiol metabolite. Critically, prasugrel's bioactivation is not CYP2C19-dependent — CYP2C19 PM patients generate active prasugrel metabolite as effectively as EM patients, and PRU values in prasugrel-treated CYP2C19 PMs are equivalent to those in EMs. The TRITON-TIMI 38 trial demonstrated prasugrel's superiority over clopidogrel in ACS patients undergoing PCI — a benefit driven disproportionately by CYP2C19 loss-of-function allele carriers. However, prasugrel carries important contraindications established in TRITON-TIMI 38: prior stroke or TIA (absolute contraindication — net clinical harm from increased intracranial hemorrhage); age ≥75 years (relative contraindication — increased bleeding risk without proportionate benefit); body weight <60 kg (relative contraindication — consider reduced dose of 5 mg). Ticagrelor is a cyclopentyl-triazolo-pyrimidine (CPTP) that is a direct-acting, reversible P2Y12 receptor antagonist — it does not require hepatic bioactivation and its mechanism is entirely independent of CYP2C19 genotype. Ticagrelor directly binds an allosteric site on P2Y12 receptors (distinct from the ADP binding site), producing potent and consistent platelet inhibition regardless of CYP2C19 status. The PLATO trial demonstrated ticagrelor's superiority over clopidogrel in ACS. In East Asian populations, there is accumulating evidence from the TICAKOREA and similar trials that ticagrelor may provide superior outcomes with an acceptable bleeding risk profile compared to prasugrel in Asian STEMI patients. Option A is incorrect — prasugrel does not require CYP2C19 and ticagrelor is not a CYP2C19 substrate; both are effective alternatives in CYP2C19 PMs. Option C is incorrect — neither prasugrel nor ticagrelor depends on CYP2C19 bioactivation. Option D is incorrect — prasugrel is a prodrug (not directly active) activated by CYP3A4/2B6; ticagrelor does not require CYP2C19 bioactivation. Option E is incorrect — ticagrelor's reversible mechanism does not create clinically significant daily windows of inadequate inhibition at twice-daily dosing; both PLATO trial data and clinical practice confirm its efficacy for stent thrombosis prevention.

3. The cardiologist switches the patient to ticagrelor 90 mg twice daily. Three months later, the patient develops a urinary tract infection and is prescribed clarithromycin by his general practitioner, who is unaware of the ticagrelor change. Ticagrelor is a CYP3A4 substrate. Which of the following best predicts the pharmacokinetic consequence of clarithromycin on ticagrelor and its clinical significance in the context of this post-stent patient?

A) Clarithromycin, as a CYP3A4 inducer, will increase ticagrelor metabolism, reducing its plasma concentrations and potentially exposing the patient to inadequate platelet inhibition and stent thrombosis risk — the same pharmacogenomic concern as clopidogrel in a CYP2C19 poor metabolizer
B) Clarithromycin is a potent CYP3A4 inhibitor; co-administration with ticagrelor (a CYP3A4 substrate) will reduce ticagrelor clearance, increasing ticagrelor and its active metabolite AR-C124910XX plasma concentrations substantially — elevated ticagrelor exposure increases the risk of bleeding (ticagrelor's primary adverse effect at supratherapeutic concentrations), dyspnea (a class-specific ticagrelor adverse effect mediated through adenosine reuptake inhibition), and bradycardia; the general practitioner should be informed and an alternative antibiotic without CYP3A4 inhibitory activity (such as trimethoprim-sulfamethoxazole or nitrofurantoin for uncomplicated UTI) should be substituted
C) Clarithromycin is a CYP3A4 substrate that competes with ticagrelor for CYP3A4 binding — this pharmacokinetic competition reduces ticagrelor metabolism, increasing its plasma concentrations; however, the interaction is clinically negligible because ticagrelor has a wide therapeutic index and elevated plasma concentrations are well-tolerated without dose adjustment
D) Because ticagrelor does not require CYP2C19 bioactivation, it is unaffected by any cytochrome P450 interaction — CYP3A4 inhibition by clarithromycin has no pharmacokinetic effect on ticagrelor plasma concentrations
E) Clarithromycin inhibits P-glycoprotein, reducing ticagrelor efflux from intestinal epithelial cells and increasing its oral bioavailability; however, this pharmacokinetic effect is offset by clarithromycin's concomitant CYP3A4 induction, which accelerates ticagrelor systemic clearance — the net pharmacokinetic effect is neutral and no dose adjustment is needed

ANSWER: B

Rationale:

This question illustrates that ticagrelor's independence from CYP2C19 (conferring pharmacogenomic advantage over clopidogrel) does not exempt it from pharmacokinetic drug interactions at other cytochrome P450 enzymes. Ticagrelor is extensively metabolized by hepatic CYP3A4, and its major circulating active metabolite AR-C124910XX is also generated by CYP3A4. This creates an important clinical vulnerability: potent CYP3A4 inhibitors substantially increase ticagrelor and AR-C124910XX plasma concentrations. Clarithromycin is one of the most potent mechanism-based CYP3A4 inhibitors in clinical use — pharmacokinetic studies demonstrate that clarithromycin co-administration increases ticagrelor AUC by approximately 2.5–4 fold. The clinical consequences of supratherapeutic ticagrelor concentrations include: increased bleeding risk (ticagrelor prolongs skin bleeding time and increases major bleeding events in a concentration-dependent manner); dyspnea (a unique class-specific adverse effect of ticagrelor affecting approximately 13% of patients at therapeutic concentrations, mediated through inhibition of equilibrative nucleoside transporter-1 and consequent adenosine accumulation — this effect is amplified at supratherapeutic concentrations); and ventricular pauses (bradyarrhythmias mediated through adenosine-dependent SA nodal effects, more common during the first week of therapy). Ticagrelor prescribing information explicitly contraindicates strong CYP3A4 inhibitors (including clarithromycin, itraconazole, ketoconazole, nefazodone, ritonavir, and saquinavir). The appropriate management is to substitute clarithromycin with an antibiotic without clinically significant CYP3A4 inhibitory activity — for uncomplicated UTI, nitrofurantoin or trimethoprim-sulfamethoxazole are appropriate alternatives (noting TMP-SMX's separate interaction profile with other medications, which must be assessed). Option A is incorrect — clarithromycin is a CYP3A4 inhibitor, not inducer; enzyme inducers reduce drug exposure, not inhibitors. Option C is incorrect — ticagrelor does not have a wide therapeutic index; the FDA and EMA explicitly contraindicate strong CYP3A4 inhibitors with ticagrelor due to clinically significant bleeding and adverse effect risk. Option D is incorrect — ticagrelor's independence from CYP2C19 does not make it immune to CYP3A4 interactions; CYP3A4 is the primary route of ticagrelor elimination. Option E is incorrect — clarithromycin does not induce CYP3A4; it is a CYP3A4 inhibitor; the described bidirectional "neutral" effect is pharmacologically incorrect.

4. At a grand rounds presentation of this case, the cardiology fellow asks what integrative lesson about the relationship between pharmacogenomics, conventional pharmacokinetic drug interactions, and clinical prescribing can be drawn from the patient's complete clinical course. Which of the following best captures this integrative lesson?

A) The case demonstrates that pharmacogenomic testing should replace all conventional therapeutic drug monitoring and platelet function testing — once pharmacogenomic results are available, no further laboratory monitoring is needed to guide antiplatelet therapy in post-PCI patients
B) The case illustrates that pharmacogenomic independence from one enzyme (CYP2C19 independence of ticagrelor) does not confer immunity from pharmacokinetic interactions at other enzymes (CYP3A4 inhibition by clarithromycin); pharmacogenomics and conventional drug interaction pharmacokinetics are complementary — not alternative — systems of drug response prediction; optimal prescribing requires integrating genotype-guided drug selection with ongoing vigilance for conventional pharmacokinetic drug interactions in the selected alternative agent
C) The case demonstrates that all antiplatelet agents are interchangeable from a pharmacogenomic perspective — the choice between clopidogrel, prasugrel, and ticagrelor should be based exclusively on cost and formulary availability rather than on pharmacogenomic or pharmacokinetic considerations
D) The primary lesson is that pharmacogenomic testing is only clinically useful before the first prescription — once a patient is stable on a drug regimen, subsequent drug additions can be made without pharmacogenomic or pharmacokinetic review
E) The case demonstrates that point-of-care platelet function testing (PRU measurement) is superior to pharmacogenomic testing in all clinical contexts and should be the sole basis for antiplatelet therapy decision-making, rendering CYP2C19 genotyping obsolete in contemporary post-PCI management

ANSWER: B

Rationale:

This case traces a pharmacologically instructive clinical arc that illuminates the complementary and non-substitutable roles of pharmacogenomics and conventional pharmacokinetic drug interaction monitoring. Phase 1 — pharmacogenomic failure: CYP2C19 *2/*2 PM status rendered clopidogrel pharmacogenomically ineffective, creating HTPR (PRU 248) and unrecognized stent thrombosis risk despite apparent treatment compliance. This was a pharmacogenomic problem requiring a pharmacogenomic solution — selection of a P2Y12 inhibitor not dependent on CYP2C19 bioactivation. Phase 2 — pharmacogenomics applied correctly: ticagrelor was selected precisely because of its CYP2C19 independence — a pharmacogenomically guided prescribing decision. Phase 3 — conventional pharmacokinetic interaction: despite pharmacogenomic optimization of ticagrelor selection, a conventional CYP3A4-mediated drug interaction with clarithromycin arose — a problem entirely independent of the patient's CYP2C19 genotype. This interaction required conventional pharmacokinetic drug interaction surveillance, not pharmacogenomic testing. The integrative lesson is that pharmacogenomics and pharmacokinetic drug interaction monitoring are complementary systems that address different layers of interindividual drug response variability. Pharmacogenomics addresses constitutional (genetically determined) differences in metabolic enzyme activity, transporter function, and drug target sensitivity. Conventional pharmacokinetics addresses environmentally determined changes in enzyme activity from concurrent drug exposures, disease states, and physiological perturbations. Sound pharmacological prescribing requires both systems operating simultaneously — neither can substitute for the other. Option A is incorrect — pharmacogenomic testing complements but does not replace platelet function testing and therapeutic monitoring; PRU measurement provided real-time phenotypic confirmation that CYP2C19 PM status was clinically consequential. Option C is incorrect — the pharmacogenomic and pharmacokinetic profiles of clopidogrel, prasugrel, and ticagrelor differ substantially in ways that are directly clinically relevant and determine appropriate patient selection. Option D is incorrect — pharmacokinetic drug interactions arise dynamically whenever new medications are added; ongoing vigilance is required throughout the treatment course, not only at initial prescription. Option E is incorrect — pharmacogenomic testing and platelet function testing are complementary; pharmacogenomic testing provides predictive, constitutional information available at any time before prescribing; PRU testing provides phenotypic confirmation but requires the drug to already be administered.

5. Case 2: The Psychiatry Consultation A 34-year-old woman of Northern European descent is referred to a psychiatry clinic for management of major depressive disorder (MDD) that has failed to respond adequately to two consecutive adequate trials of antidepressants — sertraline (12 weeks at 200 mg/day) and venlafaxine (16 weeks at 225 mg/day). She reports partial response to both but persistent residual symptoms. She has no history of bipolar disorder, psychosis, or suicidality. Her current medications include sertraline 100 mg/day (ongoing) and the oral contraceptive pill (ethinylestradiol-levonorgestrel). Her internist has ordered a comprehensive pharmacogenomic panel, which returns the following results: CYP2D6: *1/*1 (extensive metabolizer); CYP2C19: *17/*17 (ultrarapid metabolizer); CYP3A4: wild-type (extensive metabolizer); HLA-A*3101: positive carrier. The psychiatrist reviews the pharmacogenomic results and identifies CYP2C19 *17/*17 ultrarapid metabolizer status as potentially relevant to the patient's antidepressant treatment failures. Which of the following best explains the pharmacogenomic mechanism by which CYP2C19 UM status may have contributed to inadequate antidepressant response to sertraline, and what prescribing adjustment is most appropriate?

A) CYP2C19 *17/*17 ultrarapid metabolizer status increases CYP2C19 enzyme activity, accelerating the metabolism of sertraline to its pharmacologically inactive N-desmethylsertraline metabolite — the resulting low sertraline plasma concentrations may be insufficient to achieve adequate serotonin reuptake inhibition despite compliance with prescribed doses; CPIC recommends considering a higher sertraline dose or switching to an antidepressant not primarily metabolized by CYP2C19 in UM patients
B) CYP2C19 *17/*17 ultrarapid metabolizer status reduces CYP2C19 enzyme activity, causing sertraline accumulation to supratherapeutic concentrations — the resulting excessive serotonin reuptake inhibition paradoxically causes treatment-emergent anxiety and emotional blunting, which may be misinterpreted as non-response
C) CYP2C19 *17/*17 status has no relevance to sertraline pharmacology because sertraline is exclusively metabolized by CYP3A4 — the treatment failures are attributable to pharmacodynamic resistance at the serotonin transporter rather than pharmacokinetic factors
D) CYP2C19 *17/*17 ultrarapid metabolizer status converts sertraline from a serotonin reuptake inhibitor to a norepinephrine reuptake inhibitor through accelerated N-demethylation — the resulting pharmacodynamic shift explains the partial rather than full response and mandates switching to a pure SNRI such as duloxetine
E) CYP2C19 *17/*17 ultrarapid metabolizer status increases formation of the sertraline active metabolite desmethylsertraline, which is 3–5 times more potent than the parent compound as a serotonin reuptake inhibitor — UM patients therefore have enhanced antidepressant response and sertraline treatment failure in a UM patient categorically excludes pharmacokinetic factors as a cause of non-response

ANSWER: A

Rationale:

Sertraline is primarily metabolized by CYP2C19 (with secondary contributions from CYP2D6, CYP3A4, and CYP2B6) via N-demethylation to N-desmethylsertraline. N-desmethylsertraline has significantly lower serotonin reuptake inhibition potency than the parent compound (approximately 5–10 times less potent) and is considered pharmacologically inactive for clinical purposes. In CYP2C19 *17/*17 ultrarapid metabolizers, markedly elevated CYP2C19 enzyme activity accelerates sertraline N-demethylation, producing lower steady-state sertraline plasma concentrations and higher N-desmethylsertraline concentrations at any given dose. Multiple pharmacokinetic studies confirm that CYP2C19 UMs have sertraline plasma concentrations approximately 50–65% lower than extensive metabolizers at equivalent doses — concentrations that may fall below the threshold for adequate serotonin transporter occupancy required for antidepressant efficacy. This pharmacogenomic explanation does not definitively prove that UM status caused the treatment failure (multiple pharmacodynamic, psychosocial, and comorbidity factors contribute to antidepressant response), but it provides a pharmacokinetically plausible mechanism that warrants clinical consideration. CPIC guidelines (Level B evidence for CYP2C19-sertraline) suggest that CYP2C19 UMs consider a higher sertraline dose or an antidepressant whose pharmacokinetics are less influenced by CYP2C19 — for example, mirtazapine (primarily CYP1A2, CYP2D6, CYP3A4), bupropion (primarily CYP2B6), or agomelatine. The same CYP2C19 UM reasoning applies to escitalopram and citalopram, which are also primary CYP2C19 substrates and for which CPIC provides Level A recommendations — UM patients may have inadequate exposure at standard doses and require dose increases or alternative agents. Option B is incorrect — *17/*17 is a gain-of-function (ultrarapid) genotype that increases, not decreases, enzyme activity, producing lower not higher drug concentrations. Option C is incorrect — CYP2C19 is a major metabolic pathway for sertraline; dismissing it as irrelevant because CYP3A4 also contributes is pharmacologically inaccurate. Option D is incorrect — N-demethylation of sertraline to desmethylsertraline does not change the drug's receptor selectivity profile; the product remains a serotonin reuptake inhibitor class compound, not a norepinephrine reuptake inhibitor. Option E is incorrect — N-desmethylsertraline is substantially less potent than sertraline, not more potent; UM status produces inadequate antidepressant exposure, not enhanced response.

6. The pharmacogenomic panel also returns HLA-A*3101 positive carrier status. The psychiatrist considers adding carbamazepine as an augmentation strategy for treatment-resistant depression. Which of the following best integrates the HLA-A*3101 result, the patient's ancestry, and the available pharmacogenomic evidence into a prescribing recommendation?

A) HLA-A*3101 is a pharmacogenomic marker for carbamazepine hypersensitivity in patients of East Asian descent — since this patient is of Northern European descent, the HLA-A*3101 result is ethnographically inconsistent and likely represents a laboratory error; carbamazepine can be prescribed without concern
B) HLA-A*3101 positive carrier status indicates this patient has substantially elevated risk of carbamazepine-induced hypersensitivity reactions across a spectrum of severity including maculopapular exanthema (MPE), DRESS, SJS, and TEN; HLA-A*3101 is clinically relevant across multiple ancestral groups including European, Japanese, and Korean populations; CPIC guidelines recommend avoiding carbamazepine in HLA-A*3101 carriers if equally effective alternatives exist — for treatment-resistant depression augmentation, alternative strategies (lithium, atypical antipsychotics, lamotrigine) that do not carry HLA-A*3101-associated SCAR risk are preferred
C) HLA-A*3101 positive status specifically predicts carbamazepine-induced aplastic anemia rather than cutaneous reactions in European populations — the prescribing response is regular CBC monitoring rather than carbamazepine avoidance, as cutaneous reactions are not associated with this allele in non-Asian populations
D) HLA-A*3101 carries the same pharmacogenomic risk as HLA-B*1502 for carbamazepine-induced SJS/TEN in all populations — the two alleles are functionally equivalent pharmacogenomic biomarkers and a positive result for either should trigger identical prescribing responses
E) HLA-A*3101 positive status contraindicates carbamazepine use only in patients who have previously experienced a carbamazepine-induced hypersensitivity reaction — in treatment-naive patients such as this one, HLA-A*3101 status does not affect the prescribing decision and carbamazepine can be initiated with standard monitoring

ANSWER: B

Rationale:

HLA-A*3101 is a clinically actionable pharmacogenomic biomarker for carbamazepine-associated hypersensitivity reactions, with important distinctions from HLA-B*1502. While HLA-B*1502 is associated with the most severe carbamazepine reactions (SJS/TEN) predominantly in East and Southeast Asian populations, HLA-A*3101 is associated with a broader spectrum of carbamazepine hypersensitivity — including maculopapular exanthema (MPE, the most common), DRESS, SJS, and TEN — across a wider range of ancestral groups. Key characteristics of HLA-A*3101: prevalence approximately 5–12% in Northern European populations (compared to <1% prevalence of HLA-B*1502 in Europeans); odds ratio for carbamazepine hypersensitivity approximately 8–25 depending on reaction severity and population studied; clinically relevant across European, Japanese, Korean, and other non-Han Chinese populations. CPIC Level A evidence supports clinical action for HLA-A*3101: if a patient is HLA-A*3101 positive, CPIC recommends avoiding carbamazepine and using an alternative if clinically feasible. For treatment-resistant depression augmentation, multiple alternatives exist: lithium augmentation (Level I evidence in MDD); atypical antipsychotic augmentation (aripiprazole, quetiapine, olanzapine — FDA-approved adjunctive therapies for MDD); lamotrigine augmentation (evidence-based for bipolar depression and emerging evidence for unipolar MDD); thyroid hormone augmentation (liothyronine); ECT in severe refractory cases. These alternatives carry no HLA-A*3101-associated SCAR risk. The presence of an effective and safer alternative makes avoiding carbamazepine in this HLA-A*3101 positive patient the clear pharmacogenomically guided recommendation. Option A is incorrect — HLA-A*3101 is present in Northern European populations at approximately 5–12% prevalence and is pharmacogenomically relevant in this ancestry group; the result is not a laboratory error. Option C is incorrect — HLA-A*3101 is associated with cutaneous hypersensitivity reactions (MPE, DRESS, SJS/TEN), not specifically aplastic anemia in European populations; regular CBC monitoring does not address the SCAR risk. Option D is incorrect — HLA-A*3101 and HLA-B*1502 are different HLA alleles with different population prevalences, different reaction spectra, and different magnitudes of associated risk; they are not functionally equivalent biomarkers. Option E is incorrect — HLA-A*3101 pharmacogenomic risk applies to all carbamazepine-naive patients considering treatment initiation; it is a predictive biomarker, not a retrospective diagnostic marker for those who have already reacted.

7. The psychiatrist decides to avoid carbamazepine given the HLA-A*3101 positive result and instead proposes switching from sertraline to escitalopram at an increased dose, acknowledging that escitalopram is also a CYP2C19 substrate and the patient's UM status may require dose adjustment. The patient's concurrent oral contraceptive pill (OCP — ethinylestradiol-levonorgestrel) is also reviewed. Which of the following best identifies a clinically important pharmacokinetic interaction between an antidepressant commonly used in this patient's situation and the OCP?

A) Escitalopram inhibits CYP3A4, reducing ethinylestradiol metabolism and increasing OCP hormone plasma concentrations — the patient is at risk of OCP-related adverse effects including thromboembolism and should switch to a progestogen-only pill
B) Ethinylestradiol induces CYP2C19, further accelerating escitalopram metabolism in this already CYP2C19 ultrarapid metabolizer — the combined pharmacogenomic and pharmacokinetic CYP2C19 induction would produce escitalopram plasma concentrations too low for therapeutic effect, and a non-CYP2C19-metabolized antidepressant should be used
C) The OCP does not interact pharmacokinetically with escitalopram — the clinically important interaction is pharmacodynamic: ethinylestradiol upregulates serotonin transporter expression in the CNS, reducing escitalopram's serotonergic efficacy through a receptor-level pharmacodynamic antagonism that is not predicted by pharmacogenomic testing
D) St. John's Wort, if used by the patient as a complementary antidepressant, would be the most important pharmacokinetic concern — St. John's Wort is a potent CYP3A4 inducer that would reduce ethinylestradiol plasma concentrations and reduce OCP efficacy, risking unintended pregnancy; this pharmacokinetic interaction with the OCP is clinically more significant than any interaction between escitalopram and the OCP, and should be specifically asked about in this patient seeking treatment for depression who may be using complementary therapies
E) Escitalopram induces CYP2C19, converting the patient from a UM to an EM phenotype and normalizing escitalopram plasma concentrations — no dose adjustment above standard is needed in CYP2C19 UM patients receiving escitalopram

ANSWER: D

Rationale:

This question introduces a pharmacokinetic interaction that is clinically critical but often overlooked in psychiatric practice: the impact of St. John's Wort (Hypericum perforatum) on the OCP and on psychiatric medications. While escitalopram does not have clinically significant pharmacokinetic interactions with ethinylestradiol-levonorgestrel OCPs (escitalopram is metabolized by CYP2C19 and CYP3A4, neither of which is meaningfully inhibited or induced by OCP hormones at physiological concentrations), the question correctly highlights that patients with treatment-resistant depression frequently explore complementary and alternative therapies — St. John's Wort is among the most commonly self-administered herbal remedies for depression globally. St. John's Wort contains hyperforin, a potent activator of the pregnane X receptor (PXR), which transcriptionally upregulates CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein. CYP3A4 induction by St. John's Wort dramatically accelerates the hepatic and intestinal metabolism of ethinylestradiol and levonorgestrel — reducing OCP hormone plasma concentrations by 40–60%, below the threshold for reliable ovulation suppression and contraceptive protection. Well-documented OCP failures and unintended pregnancies have been reported with concurrent St. John's Wort use. Additionally, St. John's Wort may reduce escitalopram plasma concentrations through CYP2C19 induction (compounding the existing UM-related low exposure) and carries pharmacodynamic risk of serotonin syndrome when combined with SSRIs through additive serotonergic mechanisms. Specifically eliciting St. John's Wort use is mandatory in a patient with treatment-resistant depression — many patients do not consider herbal products as "medications" and will not volunteer this information unless directly asked. Option A is incorrect — escitalopram is not a clinically significant CYP3A4 inhibitor; it does not meaningfully increase ethinylestradiol concentrations. Option B is incorrect — ethinylestradiol does not induce CYP2C19 at physiological concentrations; this is not a recognized pharmacokinetic interaction. Option C is incorrect — no established pharmacodynamic interaction between ethinylestradiol and serotonin transporter expression at clinical OCP doses has been demonstrated. Option E is incorrect — escitalopram does not induce CYP2C19; it is a CYP2C19 substrate and weak inhibitor at high doses, not an inducer.

8. Reviewing the complete pharmacogenomic panel and clinical course, the supervising psychiatrist uses this case to teach registrars about the clinical implementation of pharmacogenomic testing in psychiatry. Which of the following best summarizes the appropriate role of pharmacogenomic testing in psychiatric prescribing, and its most important current limitation?

A) Pharmacogenomic testing in psychiatry provides a complete and definitive prediction of antidepressant response — a positive pharmacogenomic panel result guarantees treatment success with the genotype-matched medication, and patients whose pharmacogenomic panel does not identify a metabolizer variant can be assured of antidepressant response at standard doses
B) Pharmacogenomic testing in psychiatry — particularly CYP2D6, CYP2C19, and CYP3A4 metabolizer status — provides clinically actionable information about expected drug plasma concentrations and potential for pharmacokinetic treatment failure or toxicity; it can guide drug selection and dose optimization to avoid pharmacokinetic barriers to response; however, it does not predict pharmacodynamic antidepressant response (which depends on receptor polymorphisms, neural circuit function, psychosocial factors, and disease heterogeneity that are not captured by current metabolizer testing) and should be integrated with clinical judgment, therapeutic drug monitoring, and longitudinal symptom assessment rather than replacing any of these
C) Pharmacogenomic testing in psychiatry is most valuable for predicting antipsychotic tardive dyskinesia risk through CYP2D6 genotyping — it has no established clinical utility for antidepressant prescribing and should not be ordered in patients with MDD
D) Current pharmacogenomic testing panels capture all clinically relevant genetic variation affecting psychiatric drug response, including pharmacodynamic variants at serotonin receptors, dopamine receptors, and the serotonin transporter — a normal pharmacogenomic panel result therefore excludes pharmacogenomic factors as contributors to treatment failure
E) The primary clinical use of pharmacogenomic testing in psychiatry is to identify patients at risk of serotonin syndrome — CYP2D6 and CYP2C19 genotyping identifies patients who accumulate serotonergic drugs to dangerous levels, and all positive results mandate switching to non-serotonergic antidepressants such as mirtazapine or bupropion

ANSWER: B

Rationale:

This question addresses the appropriate epistemic framework for integrating pharmacogenomic testing into psychiatric prescribing — acknowledging both the genuine clinical value and the important current limitations. The clinical utility of pharmacogenomic metabolizer testing in psychiatry is well-established at the pharmacokinetic level: CYP2D6 and CYP2C19 genotyping predicts the likelihood that a patient will achieve therapeutic plasma concentrations of a prescribed antidepressant at standard doses. This is clinically actionable information — in this case, CYP2C19 *17/*17 UM status provided a plausible pharmacokinetic explanation for inadequate sertraline and potentially escitalopram exposure, informing the decision to either dose-escalate or switch to a non-CYP2C19-substrate antidepressant. HLA testing (HLA-A*3101) contributed clinically actionable safety information, preventing prescription of carbamazepine that carried elevated SCAR risk. However, the critical limitation that registrars must internalize is that pharmacokinetic metabolizer testing does not predict pharmacodynamic antidepressant response. Antidepressant efficacy depends on: receptor-level pharmacodynamics (serotonin transporter polymorphisms such as 5-HTTLPR, serotonin receptor variants, brain-derived neurotrophic factor Val66Met polymorphism — variants not captured by metabolizer testing panels); neural circuit neuroplasticity; psychosocial and environmental factors; disease heterogeneity within the MDD diagnosis (MDD is likely multiple distinct biological entities sharing phenotypic features); and comorbid conditions. A patient can have normal CYP metabolizer status and still fail multiple antidepressants due to pharmacodynamic factors — and conversely, addressing pharmacokinetic barriers does not guarantee pharmacodynamic response. This case illustrates the appropriate integration: pharmacogenomics identified a pharmacokinetic barrier (UM CYP2C19 reducing sertraline exposure) and a safety concern (HLA-A*3101 contraindicating carbamazepine), while clinical judgment, therapeutic monitoring, and symptom assessment guide the overall treatment strategy. Option A is incorrect — pharmacogenomic testing does not guarantee treatment success; it addresses pharmacokinetic barriers, not pharmacodynamic response determinants. Option C is incorrect — CYP2D6 and CYP2C19 metabolizer testing has well-established clinical utility for antidepressant prescribing, supported by CPIC Level A and B evidence for multiple antidepressants. Option D is incorrect — current commercial pharmacogenomic panels primarily capture metabolizer enzyme polymorphisms; most do not include validated pharmacodynamic receptor polymorphisms, which remain largely in the research domain; a normal metabolizer panel does not exclude all pharmacogenomic contributions to treatment failure. Option E is incorrect — the primary utility of CYP2D6/CYP2C19 testing in psychiatry is dose and drug selection optimization, not serotonin syndrome prediction; CYP UM status does not mandate switching to non-serotonergic agents as a class.